Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 16 | 2025 | 128 | 4.380 |
Why?
|
| Cadherins | 12 | 2025 | 200 | 2.470 |
Why?
|
| Antigens, CD | 10 | 2025 | 558 | 2.120 |
Why?
|
| Carcinoma, Signet Ring Cell | 6 | 2025 | 17 | 1.570 |
Why?
|
| Adenocarcinoma | 7 | 2023 | 926 | 1.090 |
Why?
|
| Germ-Line Mutation | 11 | 2025 | 177 | 1.020 |
Why?
|
| Gastrectomy | 8 | 2024 | 166 | 0.930 |
Why?
|
| Carcinoma, Lobular | 2 | 2025 | 56 | 0.880 |
Why?
|
| Rabies | 2 | 2022 | 4 | 0.750 |
Why?
|
| Dog Diseases | 2 | 2022 | 106 | 0.680 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2025 | 2399 | 0.650 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2021 | 47 | 0.650 |
Why?
|
| Bone Density | 1 | 2023 | 487 | 0.600 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2018 | 44 | 0.550 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 70 | 0.540 |
Why?
|
| Calcium | 1 | 2023 | 1191 | 0.510 |
Why?
|
| Primary Prevention | 1 | 2018 | 222 | 0.490 |
Why?
|
| Breast Neoplasms | 4 | 2025 | 2393 | 0.480 |
Why?
|
| Peritoneal Neoplasms | 2 | 2022 | 104 | 0.320 |
Why?
|
| Vaccination | 1 | 2018 | 1428 | 0.300 |
Why?
|
| Loss of Function Mutation | 2 | 2024 | 45 | 0.230 |
Why?
|
| Genetic Testing | 2 | 2025 | 483 | 0.220 |
Why?
|
| Calcium, Dietary | 1 | 2023 | 52 | 0.200 |
Why?
|
| Femur Neck | 1 | 2023 | 62 | 0.190 |
Why?
|
| Phosphorus | 1 | 2023 | 90 | 0.190 |
Why?
|
| One Health | 1 | 2022 | 10 | 0.180 |
Why?
|
| Vitamins | 1 | 2023 | 184 | 0.180 |
Why?
|
| Humans | 21 | 2025 | 145763 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2022 | 120 | 0.170 |
Why?
|
| Dogs | 2 | 2022 | 478 | 0.170 |
Why?
|
| Carcinoma | 1 | 2022 | 227 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 1 | 2022 | 142 | 0.160 |
Why?
|
| Peritoneal Lavage | 1 | 2019 | 8 | 0.150 |
Why?
|
| Vitamin D | 1 | 2023 | 404 | 0.150 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 42 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2023 | 584 | 0.150 |
Why?
|
| Asia | 1 | 2018 | 70 | 0.140 |
Why?
|
| Counseling | 1 | 2022 | 401 | 0.140 |
Why?
|
| Africa | 1 | 2018 | 119 | 0.140 |
Why?
|
| Middle Aged | 8 | 2025 | 36302 | 0.140 |
Why?
|
| Zoonoses | 1 | 2018 | 39 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2024 | 8075 | 0.140 |
Why?
|
| Endoscopy | 1 | 2020 | 317 | 0.130 |
Why?
|
| Hepatectomy | 1 | 2020 | 274 | 0.130 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2022 | 549 | 0.120 |
Why?
|
| Emotions | 1 | 2022 | 577 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 373 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2024 | 3752 | 0.110 |
Why?
|
| Biomarkers | 2 | 2023 | 4302 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2019 | 481 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 8346 | 0.100 |
Why?
|
| Female | 12 | 2025 | 79035 | 0.100 |
Why?
|
| Male | 11 | 2025 | 73003 | 0.100 |
Why?
|
| Aged | 6 | 2024 | 26215 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1329 | 0.090 |
Why?
|
| Adult | 6 | 2025 | 40872 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17325 | 0.060 |
Why?
|
| Survival Rate | 2 | 2022 | 2094 | 0.060 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2024 | 7 | 0.050 |
Why?
|
| Penetrance | 1 | 2024 | 30 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 45 | 0.050 |
Why?
|
| Gastric Mucosa | 1 | 2023 | 54 | 0.050 |
Why?
|
| Heterozygote | 1 | 2024 | 314 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 69 | 0.040 |
Why?
|
| Adolescent | 1 | 2022 | 22573 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 228 | 0.040 |
Why?
|
| India | 1 | 2022 | 213 | 0.040 |
Why?
|
| Gastroscopy | 1 | 2020 | 18 | 0.040 |
Why?
|
| Stomach | 1 | 2020 | 111 | 0.040 |
Why?
|
| Animals | 2 | 2022 | 38097 | 0.040 |
Why?
|
| Cytodiagnosis | 1 | 2019 | 31 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 528 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 1270 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 735 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 644 | 0.040 |
Why?
|
| Transcriptome | 1 | 2025 | 1042 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 230 | 0.040 |
Why?
|
| Phenotype | 1 | 2025 | 3170 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1547 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1474 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 904 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1969 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2977 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 3210 | 0.020 |
Why?
|
| Prognosis | 1 | 2020 | 4329 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5428 | 0.020 |
Why?
|
| United States | 1 | 2019 | 16123 | 0.010 |
Why?
|